Biomarkers in Heart Failure. Does Prognostic Utility Translate to Clinical Futility?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 11, 2007, Pages 1061-1063

  Maisel, Alan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GROWTH DIFFERENTIATING FACTOR 15; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

CLINICAL EVALUATION; CLINICAL FEATURE; DEFIBRILLATOR; DYSPNEA; EDITORIAL; HEART FAILURE; HUMAN; LABORATORY TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS;

BIOLOGICAL MARKERS; BONE MORPHOGENETIC PROTEINS; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 34548304084     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.05.032     Document Type: Editorial

References (22)

1. Xu J., Kimball T.R., Lorenz J.N., et al. GDF-15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98 (2006) 342-350
2. Kempf T., Eden M., Strelau J., et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98 (2006) 351-360
3. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
4. Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005) 948-954
5. Publication Committee for the VMAC Investigators (Vasodilation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for the treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
6. Maisel A., Hollander J.E., Guss D., et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 (2004) 1328-1333
7. Kazanegra R., Cheng V., Garcia A., et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 7 (2001) 21-29
8. Liang F., O'Rear J., Schellengerger U., et al. Evidence for functional heterogeneity of circulating BNP. J Am Coll Cardiol 49 (2007) 1071-1078
9. Hawkridge A.M., Heublein D.M., Bergen III H.R., Cataliotti A., Burnett Jr. J.R., and Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A 102 (2005) 17442-17447
10. Cheng V., Kazanagra R., Garcia A., et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37 (2001) 386-391
11. Logeart D., Thabut G., Tartiere J.M., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
12. O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 13 (2007) 50-55
13. Anand I.S., Fisher L.D., Chiang Y.T., et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
14. Troughton R.W., Frampton C.M., Yandle T.G., et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
15. Jourdain P., Jondeau G., Funck F., et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 49 (2007) 1733-1739
16. Berger R., Huelsman M., Strecker K., et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105 (2002) 2392-2397
17. Klingenberg R., Zugck C., Becker R., et al. Raised B-type natriuretic peptide predicts implantable cardioverter-defibrillator therapy in patients with ischaemic cardiomyopathy. Heart 92 (2006) 1323-1324
18. Lellouche N., De Diego C., Cesario D.A., et al. Usefulness of preimplantation B-type natriuretic peptide level for predicting response to cardiac resynchronization therapy. Am J Cardiol 99 (2007) 242-246
19. Pitzalis M., Iacoviello M., Di Serio F., et al. Methodical approach to collecting and preserving plasma samples containing B-type natriuretic peptide. Eur J Heart Fail 9 (2007) 215
20. Fruhwald F.M., Fahrietner-Pammer A., Berger R., et al. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28 (2007) 1592-1597
21. Davenport C., Cheng E.Y., Kwok Y.T., Wakabayashi T., Hyde C., and Connock M. Assessing the diagnostic test accuracy of natriuretic peptides and EDG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis. Br J Gen Pract 56 (2006) 48-56
22. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50 (2007) 1054-1060